iwNHL 2015 | iwNHL 2015 roundtable: Day 2 highlights – bortezomib, proteasome inhibitor, for B-cell lymphoma
John Gribben and Wyndham Wilson
• 3 Oct 2015
John Gribben, MD, DSc, FRCPath, FRCP FMedSci, of Barts and The London School of Medicine and Dentistry, London, UK, chairs a discussion with Wyndham Wilson, MD, PhD, of the National Cancer Institute, Bethesda, MD, on the highlights from the second day of the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting. They evaluate the clinical data supporting the use of bortezomib, a proteasome inhibitor, for the treatment of patients with diffuse large B-cell lymphoma and mantle cell lymphoma.
